Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Chinese Adults, Children, and Infants
NCT07023081Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Prevnar 20 in pneumococcal disease (7 cohorts), sponsored by Pfizer. Primary endpoints: Percentage of participants reporting prespecified local reactions at 7 days, Percentage of participants reporting prespecified systemic events at 7 days and 4 more. Started Jun 2025; status: active, not recruiting.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT07023081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07023081.